VivoSeq
Immunology

Takayasu Arteritis

18

Pipeline Programs↗

4

Active Trials↗

11

Companies Involved↗

Takayasu arteritis is an emerging landscape with 18 programs across 11 companies. The most active players are Eli Lilly, Merck & Co., Johnson & Johnson. 6 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

23/100

Completion Rate

80/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 3AbbVie logo

AbbVie

1 program

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 3P

Prism Pharmaceuticals

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

12 of 18 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody633%

Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 19 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed4 · 31%
Unknown status4 · 31%
Recruiting3 · 23%
Terminated1 · 8%
Active, not recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

The Registry Study of Takayasu Arteritis in East China
Recruiting·SShanghai Zhongshan Hospital·N/A·NCT03893136·1,000 enrolled
A Pilot Study in Severe Patients With Takayasu Arteritis.
Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT04300686·40 enrolled
Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
Recruiting·MMarmara University·N/A·NCT07491913·40 enrolled
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
Active, not recruiting·AbbVie logoAbbVie·Phase 3·NCT04161898·56 enrolled
Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02101333·18 enrolled
Takayasu Arteritis Clinical Trial in China
Completed·—·N/A·NCT02981979·116 enrolled
Baricitinib for Refractory Takayasu Arteritis
Completed·—·Phase 2·NCT06662721·10 enrolled
Major Adverse Cardiovascular Events and Territory-Specific Arterial Complications in Patients With Takayasu Arteritis Compared With Matched General-Population Controls: A Nationwide Cohort Study Using the French SNDS
Completed·GGroupe français d'étude des Maladies Inflammatoires de loeil·N/A·NCT07686991·8,275 enrolled
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
Terminated·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT04882072·14 enrolled
Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis
Unknown status·SSeoul National University Hospital·Phase 2·NCT02457585·11 enrolled
Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis
Unknown status·CChinese SLE Treatment And Research Group·Phase 4·NCT05151848·100 enrolled
Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis
Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04564001·50 enrolled
Anti-inflammatory Treatment for Inactive Takayasu Arteritis
Unknown status·—·Phase 2/3·NCT03550781·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)